Mesenchymal Stem Cell-Derived Extracellular Vesicles Mitigate Immune Cell Activation in an In Vitro Model of Post-Resuscitation Inflammation
Rolland, T. J.; Zahra, S.; Cucinotta, D.; Young, R.; Weil, B. R.
Show abstract
BackgroundSystemic inflammation is a well-established component of post-cardiac arrest syndrome (PCAS), a condition responsible for significant morbidity and mortality in patients who are initially resuscitated from sudden cardiac arrest. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have emerged as promising immunomodulatory agents in various inflammatory conditions, including after ischemia-reperfusion injury (IRI). Here, we investigated the therapeutic potential of MSC-EVs in porcine peripheral blood mononuclear cells (PBMCs) stimulated with lipopolysaccharide (LPS) or mitochondrial DNA (mtDNA) to mimic immune cell activation in PCAS. MethodsPBMCs were isolated from healthy pigs (Sus scrofa), cultured in vitro, stimulated with LPS or mtDNA, and treated with a range of MSC-EV concentrations. Flow cytometry, quantitative PCR, ELISA, and ROS/RNS measurements were performed to assess PBMC activation. ResultsMSC-EV treatment reduced LPS-induced inflammatory granulocyte activation and selectively modulated cytokine transcripts, including IFN, IL-1{beta}, and TNF-, in a concentration-dependent manner. Similar immunosuppressive effects were observed in mtDNA-stimulated PBMCs, where MSC-EVs attenuated dendritic cell activation and inflammatory cytokine release. Furthermore, higher concentrations of MSC-EVs significantly decreased ROS/RNS production in both LPS- and mtDNA-challenged PBMCs. ConclusionsMSC-EVs exhibit potent immunomodulatory properties against LPS- and mtDNA-induced activation of porcine PBMCs, highlighting their broad capacity to modulate immune responses and mitigate oxidative stress induced by pro-inflammatory stimuli that are relevant to PCAS. These findings provide further support for the administration of MSCs, or MSC-EVs themselves, as a potential therapeutic intervention to target immune activation in PCAS and other disorders characterized by an acute systemic inflammatory state.
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Temporal changes in the protein cargo of extracellular vesicles and resultant immune reprogramming after severe burn injury in humans and mice. 94%
- MyD88-Dependent Signaling Drives Toll-Like Receptor-Induced Trained Immunity in Macrophages 92%
- Identification of omega-3 oxylipins in human milk-derived extracellular vesicles with pro-resolutive actions in gastrointestinal inflammation. 92%
Similar papers in this journal
- Safety and anti-inflammatory effects of ILB-202, an engineered extracellular vesicles for NF-κB inhibition: A double-blind, randomized, placebo-controlled phase 1 trial 94%
- Beyond Basic Characterization and Omics: Immunomodulatory Roles of Platelet-Derived Extracellular Vesicles Unveiled by Functional Testing 94%
- Distinct non-coding RNA cargo of extracellular vesicles from M1 and M2 human primary macrophages 93%
Similar papers in this journal
- Optimizing Cell Therapy by Sorting Cells with High Extracellular Vesicle Secretion 95%
- Dual-mode action of scalable, high-quality engineered stem cell-derived SIRPα-extracellular vesicles for treating acute liver failure 94%
- Transmembrane Stem Cell Factor Protein Therapeutics EnhanceRevascularization in Ischemia without Mast Cell Activation 94%
Similar papers in this journal
- Immune engineered extracellular vesicles to modulate T cell activation in the context of type 1 diabetes 93%
- TRAF6-IRF5 kinetics, TRIF, and biophysical factors drive synergistic innate responses to particle-mediated MPLA-CpG co-presentation 93%
- Induction of Muscle Regenerative Multipotent Stem Cells from Human Adipocytes by PDGF-AB and 5-Azacytidine. 93%
Similar papers in this journal
- Suppression of endothelial miR-22-3p mediates non-small cell lung cancer cell-induced angiogenesis 90%
- Multiplex HDR for Disease and Correction Modeling of SCID by CRISPR Genome Editing in Human HSPCs 90%
- Novel Fas-TNFR chimeras that prevents Fas ligand-mediated kill and signals synergistically to enhance CAR T-cell efficacy 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.